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<<abs>> 
Objective. Pain sensitization may contribute to pain severity in rheumatoid arthritis (RA), 
impacting disease activity assessment. We examined whether pain processing mechanisms were 
associated with disease activity among RA patients with active disease. 
Methods. The study included 139 subjects enrolled in the Central Pain in Rheumatoid Arthritis 
cohort. Subjects underwent quantitative sensory testing (QST), including assessment of pressure 
pain thresholds (PPTs) at multiple sites, conditioned pain modulation, and temporal summation. 
RA disease activity was assessed using the Clinical Disease Activity Index (CDAI) and its 
components. We examined cross-sectional associations between QST measures and disease 
activity using linear regression.  
Results. Low PPTs (high pain sensitization) at all sites were associated with high CDAI scores (P 
≤ 0.03) and tender joint counts (P ≤ 0.002). Associations between PPTs and patient global 
assessments were also seen at most sites. High temporal summation at the forearm (also 
reflecting high pain sensitization) was significantly associated with high CDAI scores (P = 0.02), 
patient global assessment scores (P = 0.0006), evaluator global assessment scores (P = 0.01), and 
tender joint counts (P = 0.02). Conversely, conditioned pain modulation (a measure of 
descending inhibitory pain pathways) was associated only with tender joint count (P = 0.03). 
Conclusion. High pain sensitization is associated with elevations in disease activity measures. 
Longitudinal studies are underway to elucidate the cause–effect relationships between pain 
sensitization and inflammatory disease activity in RA.  
<</abs>> 
 
<<hd1>>INTRODUCTION 
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Pain is often considered a surrogate marker for inflammatory disease activity in rheumatoid 
arthritis (RA). It is the single largest determinant of patient assessment of global disease activity 
(1,2). It is also a prominent component of the American College of Rheumatology 
(ACR)/European League Against Rheumatism (EULAR) criteria for remission (3,4). However, 
pain does not always equal inflammation. Evidence of this was seen in one study, in which the 
majority of established RA patients with pain (median 3 of 10 in intensity) had a minimum 
number of swollen joints (5). 
 
<<significance&innovations>> 
Significance & Innovations • This is the largest study to comprehensively assess pain sensitization in rheumatoid arthritis 
(RA), using pressure pain thresholds, temporal summation, and conditioned pain modulation, 
in a study population that draws from 5 academic medical centers across the US. • Associations between temporal summation at the forearm (a measure of central sensitization) 
and Clinical Disease Activity Index score, tender joint count, evaluator global assessment 
score, and patient global assessment score are reported for the first time. • Associations between conditioned pain modulation (a measure of descending analgesic pain 
mechanisms) and measures of disease activity in an RA population are described for the first 
time.  
 
Several studies indicate that individuals with RA have abnormalities in peripheral and 
central nervous system pain processing, resulting in widespread pain sensitivity. Four cross-
sectional studies have examined the relationship between pain thresholds and validated measures 
of disease activity in RA (6–9). All 4 studies were small (n ≤59), limiting the ability to examine 
differences in associations between subgroups of patients, such as those with secondary 
fibromyalgia. Two of the studies included only women, thereby limiting generalizability to men 
(8,9). In this study, we enrolled 139 patients across 5 sites, including 23 men. In addition, we 
also assessed conditioned pain modulation as a measure of descending analgesic pain 
mechanisms. We hypothesized that low pressure pain thresholds (PPTs), low conditioned pain 
modulation and high temporal summation would be associated with high Clinical Disease 
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Activity Index (CDAI) scores, tender joint counts, and patient global health assessment scores, 
whereas the association between pain sensitization and measures that emphasize direct 
assessment of inflammation would be low. 
 
<<hd1>>PATIENTS AND METHODS 
 
<<hd3>>Study population. The study includes baseline data from the first 139 subjects 
with complete data on disease activity measures in the Central Pain in Rheumatoid Arthritis 
(CPIRA) study. CPIRA is a multicenter, prospective, observational study designed to examine 
the relationship between pain and treatment response in RA. Participants were recruited from 5 
US academic medical centers beginning in January 2014. The inclusion criteria were as follows: 
diagnosis of RA based on the ACR/EULAR 2010 classification criteria (10); starting or 
switching to a disease-modifying antirheumatic drug (DMARD) due to active RA; and ability to 
participate in a study visit before taking the first dose of the new DMARD. An exception was 
made for participants starting methotrexate therapy. These individuals were able to participate 
after taking 1 dose of medication if they were able to come in for their study visit before taking a 
second dose. Pharmacodynamic studies indicate that the onset of action of oral methotrexate for 
RA is between 3 and 6 weeks, so a single dose of methotrexate should not alter the results of our 
study (11). For individuals switching to a different DMARD, no washout period was required. 
Exclusion criteria were as follows: changing doses of centrally acting pain medications 
(e.g., amitriptyline, gabapentin, or duloxetine) within 3 months of enrollment; corticosteroid 
treatment of >10 mg of prednisone or its equivalent; chronic opioid use or any opioid use within 
24 hours of testing; diagnosis of a systemic autoimmune disease other than RA; severe 
Raynaud’s phenomenon requiring pharmacologic treatment; severe peripheral vascular disease 
manifested by claudication or ischemic rest pain; and peripheral neuropathy. All subjects 
provided written informed consent. The institutional review boards at each site approved the 
study.  
<<hd3>>Quantitative sensory testing (QST). All assessors attended a 1-day training 
session and received in-person instruction on the use of QST. Two of the authors (YCL and 
RRE) supervised these sessions and ensured that testing measures were standardized across all 
sites. Site visits were conducted approximately 1 year into the study to ensure that standardized 
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protocols were being followed. Assessments of interrater reliability were performed among a 
subgroup of assessors (n = 4), and the intraclass correlation coefficients (ICCs) ranged from 0.71 
to 0.90 for the PPT and temporal summation measures. The ICC for conditioned pain modulation 
was 0.45. As per Cicchetti (12), ICCs 0.40–0.59 were defined as fair, 0.60–0.74 as good, and 
0.75–1.00 as excellent. A comparison of QST measures across sites is shown in Supplementary 
Table 1 (see Supplementary Table 1, available on the Arthritis Care & Research web site at 
http://onlinelibrary.wiley.com/doi/10.1002/acr.23266/abstract). 
<<hd4>> PPTs. Using a Wagner Force 10 FDX algometer, we obtained PPTs at joint 
sites (bilateral wrists and knees) and nonjoint sites (bilateral trapezius muscles and thumbnails) 
in random order, with 3 trials at each site. The 1-cm2
13
 rubber algometer probe was placed in the 
center of each anatomic site by the study staff.  The pressure was increased at a rate of 0.50 
kgf/second until the stimulus first became painful. The pressure at this point was defined as the 
PPT. To obtain the mean PPT for each site, we averaged the PPTs obtained on both sides of the 
body during all 3 trials. Low PPTs at joint sites were considered markers of peripheral 
sensitization, whereas low PPTs at both joint and nonjoint sites were considered markers of 
central sensitization ( ). 
<<hd4>>Mechanical temporal summation. Consistent with previous literature (14), 
temporal summation was assessed using a set of 6 probes, with weighted, flat-end wire tips 
measuring 0.2 mm in diameter (University of North Carolina, Chapel Hill). The weights ranged 
8–256 mN. The probes were tested on the participants by slowly touching the full weight of the 
probe against the subject’s skin at the middle of the wrist (joint site) and then the forearm 
(nonjoint site). Test taps were performed, beginning with the probe of least weight and 
sequentially increasing the probe weight until the subject reported a pain rating of 30–40/100 or 
until the heaviest probe was used. Using this probe, temporal summation was measured by 
tapping the probe against the skin at the test site 10 times, with each tap lasting approximately 
0.5 seconds and with 1 second between stimuli. The subject was asked to rate his/her pain level 
on a scale of 0–100 after the first, fifth, and tenth taps. Temporal summation was defined as the 
difference between the pain level at the tenth tap and the pain level at the first tap for each trial. 
Three trials were performed at each site. Mean temporal summation measurements at the wrist 
and the forearm were calculated by averaging the results of the 3 trials. Higher measures of 
temporal summation were considered to reflect greater central sensitization. 
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<<hd4>>Conditioned pain modulation. Conditioned pain modulation was assessed using 
a procedure that incorporates a conditioning stimulus (painful stimulus that activates the 
descending analgesic pain pathways) and a test stimulus (painful stimulus to test the analgesic 
response to the conditioning stimulus) (15,16). The conditioning stimulus was immersion of the 
right hand in a cold water bath, maintained between 5°C and 7°C. The test stimulus was pressure 
applied by an algometer at the left trapezius muscle. An initial PPT was obtained before 
immersion of the hand in the cold water bath. The subject was then instructed to place his/her 
hand in the water. After 20 seconds, the PPT at the left trapezius muscle was obtained a second 
time, immediately before the participant removed his/her hand from the water. If the participant 
was unable to keep the hand in the water for 20 seconds, the second PPT was measured 
immediately after the removal of the hand from the water. Conditioned pain modulation was 
defined as the ratio of the PPT at the second time point over the PPT at the first time point, 
multiplied by 100 (17). A result of 100 meant that there was no difference between the PPT 
before the subject was exposed to the conditioning stimulus versus the PPT after the subject was 
exposed to the conditioning stimulus. Values greater than 100 were indicative of conditioned 
pain modulation, reflecting increases in PPTs at the second time point compared to PPTs at the 
first time point. Conversely, lower values were considered to reflect abnormalities in descending 
pain inhibition. 
<<hd3>>Assessment of clinical variables. Overall RA disease activity was assessed 
using the CDAI, a composite measure that includes tender joint count, swollen joint count, 
patient global assessment, and assessor global assessment (18). We used the CDAI as the 
primary measure of RA disease activity because serum inflammatory markers (required for the 
calculation of other validated disease activity measures) will be measured after the full cohort is 
assembled and are not currently available. Joint counts and assessor global assessments were 
performed by trained study staff members. For the patient global assessment score, participants 
were asked to assign a number, using a 100-point numeric rating scale, in response to the 
question, “Considering all the ways in which your arthritis has affected you, how do you feel 
your arthritis is today?” Demographic information and RA disease characteristics were obtained 
using self-report questionnaires. Rheumatoid factor (RF) and anti–cyclic citrullinated peptide 
(anti-CCP) seropositivity were obtained using a standardized chart review process. Body mass 
index (BMI) was calculated from height and weight obtained at the time of the study visit. 
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Depression, anxiety, and sleep disturbance were assessed using Patient-Reported Outcomes 
Measurement Information System (PROMIS) computerized adaptive tests (19,20). 
Catastrophizing was assessed using the Pain Catastrophizing Scale (21). Fibromyalgia status was 
determined according to the ACR 2010 modified preliminary diagnostic criteria, which include 
meeting a score of: ≥7 on the Widespread Pain Index and ≥5 on the Symptom Severity Scale or 
3–6 on the Widespread Pain Index and ≥9 on the Symptom Severity Scale (22,23).  
<<hd3>>Statistical analysis. The primary outcome was RA disease activity, measured 
by the CDAI. Secondary outcomes included the components of the CDAI, specifically, the 
tender joint count, swollen joint count, patient global assessment, and assessor global assessment. 
The main predictors were PPTs at the wrists, knees, trapezius muscles, and thumbnails; temporal 
summation at the forearm and the wrist; and conditioned pain modulation. Potential confounders 
included age, sex, BMI, RA disease duration, RF or anti-CCP seropositivity, depression, sleep 
disturbance, and catastrophizing. 
Unadjusted associations between QST measures and clinical disease activity were 
identified using Pearson correlation coefficients. We examined the association between QST 
measures and disease activity using multivariable linear regression, after adjusting for the 
covariates listed above. The strength of association was assessed using regression coefficients (β). 
In exploratory analyses, we also examined the role of fibromyalgia as an effect modifier of the 
relationship between QST measures and disease activity. These analyses were performed using 
models stratified by fibromyalgia status, as well as models including a QST measure × 
fibromyalgia interaction term. The threshold for statistical significance was set as a 2-tailed P 
value of less than 0.05. We did not adjust for multiple comparisons because this was an 
observational, hypothesis-screening study, and adjustments for multiple testing limit the ability 
to identify potentially important findings (24). All analyses were performed using SAS, version 
9.4. 
 
<<hd1>>RESULTS 
 
<<hd3>>Patient characteristics and PPTs. There were 139 RA patients included in the 
analysis. The mean ± SD age was 54.2 ± 13.6 years, and 83.5% were women (Table 1).<<T1>> 
The mean ± SD baseline CDAI score was 24.4 ± 14.0, and 32% met the ACR 2010 modified 
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preliminary diagnostic criteria for fibromyalgia. The mean ± SD PPT was lowest at the wrists 
and trapezius muscles (2.9 ± 1.6) and highest at the knees (5.3 ± 2.7) (Table 2).<<T2>> PPTs 
were inversely associated with the CDAI, with beta coefficients ranging from −1.29 at the 
thumbnail to −3.30 at the trapezius (P ≤ 0.03) (Table 3).<<T3>> PPTs were also significantly 
associated with the tender joint count, with beta coefficients ranging from −1.09 at the thumbnail 
to −1.98 at the trapezius (P ≤ 0.002). PPTs at all sites except the thumbnail were significantly 
associated with patient global assessment scores (P ≤ 0.04). In contrast, PPTs were not 
significantly associated with the swollen joint count.  
In stratified analyses, beta coefficients for the association between PPTs and both the 
CDAI and tender joint counts were generally higher among RA patients who met the 2010 ACR 
modified preliminary criteria for fibromyalgia (β range = −1.07, −5.72), compared with those 
who did not meet the 2010 ACR modified preliminary criteria for fibromyalgia (β range = −0.81, 
−3.11). To assess the statistical significance of these differences, we performed exploratory 
analyses using multivariable linear regression models including an interaction term for PPT × 
fibromyalgia. None of the interaction terms were found to be statistically significant. 
<<hd3>>Temporal summation. The mean ± SD values for temporal summation at the 
wrist and forearm were 15.0 ± 15.3 and 14.0 ± 13.8, respectively (Table 2). Temporal summation 
at the forearm was significantly associated with the CDAI score (β = 0.19; P = 0.02), tender joint 
count (β = 0.11; P = 0.02), patient global assessment score (β = 0.05; P = 0.0006), and assessor 
global assessment score (β = 0.04; P = 0.01), whereas temporal summation at the wrist was 
significantly associated only with patient global assessment (β = 0.04; P = 0.003) (Table 
4).<<T4>> In analyses stratified by fibromyalgia status, beta coefficients for the association 
between temporal summation and CDAI score were lower among those with RA and 
fibromyalgia (β = −0.02 in forearm and β = −0.01 in wrist), compared with those with RA alone 
(β = 0.25 in forearm and β = 0.23 in wrist). The interaction terms for temporal summation × 
fibromyalgia were not statistically significant. 
<<hd3>>Conditioned pain modulation. The mean ± SD conditioned pain modulation 
ratio was 142.3 ± 39.4 (Table 2). Conditioned pain modulation was associated with tender joint 
count (β = 0.04; P = 0.03) but not with any other disease activity measure (Table 4). Analyses 
stratified by fibromyalgia status did not reveal significant differences in the beta coefficients for 
the associations between conditioned pain modulation and disease activity measures. Interaction 
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terms for conditioned pain modulation × fibromyalgia were not statistically significant. 
 
<<hd1>>DISCUSSION 
 
This study confirms previous findings showing associations between PPTs and composite 
measures of RA disease activity, tender joint count, evaluator global assessment, and patient 
global assessment (6,8,25). This study is also the first to report associations between temporal 
summation at the forearm and CDAI, tender joint count, evaluator global assessment, and patient 
global assessment. These findings suggest that pain sensitization, reflected by low PPTs and high 
temporal summation, may contribute to the amplification of patient assessment of disease 
activity and tender joint count, as well as a perception of higher activity by the evaluator.  
To provide clinical context, we compared our results to published data using the same 
techniques (e.g., same test stimulus and same conditioning stimulus). The median PPT in this 
population (2.5–4.9 kgf) was lower than that in the general population (6.2–9.4 kgf) and lower 
than that observed in an RA population with lower disease activity (5.2–8.4 kgf) (15). Temporal 
summation at the forearm (mean 14.0 ± 13.8) was higher in our population compared to healthy 
controls (mean 10.6 ± 11.3) (26). These comparisons should be interpreted with caution, given 
possible differences in study populations beyond the differences in disease state and disease 
activity levels. 
The observation that low PPTs were associated with high CDAI scores, high tender joint 
counts, and high patient global assessment scores, but not with swollen joint counts, is consistent 
with studies showing that individuals with RA and fibromyalgia score higher on composite 
disease activity measures and the individual components of tender joint count and patient global 
assessment (27–30). In our study, beta coefficients for the associations between PPTs and CDAI 
scores indicated that a 1-unit difference in PPT was associated with a 1.29–3.30 difference in 
CDAI score. The magnitude of this association was not high, given that the minimum clinically 
important difference for the CDAI is 6 for individuals with moderate disease activity and 12 for 
individuals with high disease activity (31). The strength of this association was higher among 
individuals with both RA and fibromyalgia, with a beta coefficient of −5.72 for the association 
between trapezius PPT and CDAI. However, the interaction terms between fibromyalgia and 
PPTs were not statistically significant when fibromyalgia was examined as a dichotomous 
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variable or as a continuous measure of fibromyalgia symptom severity. The lack of statistical 
significance may reflect limited statistical power, given the small number of individuals with 
fibromyalgia.  
High temporal summation at the forearm was significantly associated with high CDAI 
scores, tender joint counts, evaluator global assessment scores, and patient global assessment 
scores, but temporal summation at the wrist was associated only with patient global assessment. 
The beta coefficients for the association between temporal summation and CDAI score ranged 
from 0.07 at the wrist to 0.11 at the forearm, indicating that a 1-unit difference in temporal 
summation was associated with an increase in CDAI score of 0.07–0.11. Thus, a large difference 
in temporal summation is needed to see a relatively small difference in CDAI score.  
It was surprising that temporal summation at the wrist was not associated with disease 
activity measures, because the wrist is a site commonly affected by inflammation in RA. Thus, if 
anything, we expected stronger associations between temporal summation at the wrist and 
disease activity measures. One explanation could be that our measure of temporal summation 
was not sufficiently sensitive. Many subjects did not find the punctate probes to be painful, and 
the distribution of temporal summation, both at the forearm and the wrist, was right-skewed. We 
were not able to use a higher-weight probe due to skin fragility in a number of subjects. 
Compared to other study populations, in this RA population skin fragility may be a larger 
problem due to chronic corticosteroid use. 
To our knowledge, only one other study has examined the association between temporal 
summation and disease activity measures in RA. Using a temporal summation protocol involving 
cuff pressure algometry, Vladimirova et al assessed temporal summation at the leg in 38 women 
with active RA and found no association between the temporal summation index and tender joint 
count, swollen joint count, or Disease Activity Score in 28 joints (9). A study of 1,111 
individuals in the Multicenter Osteoarthritis Study, however, found differences in associations 
between temporal summation of mechanical stimuli at affected versus unaffected body sites and 
magnetic resonance imaging–based evaluation of inflammation (32). Over 24 months, this study 
noted a stronger association between knee effusions and incident temporal summation at the 
affected site than between knee effusions and incident temporal summation at an unaffected site. 
Additional studies, using a different method of temporal summation, may be helpful in further 
elucidating the association between temporal summation and disease activity measures in RA. 
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Contrary to the associations observed between PPTs and disease activity measures and 
temporal summation and disease activity measures, conditioned pain modulation was associated 
with tender joint count and not with any other disease activity measure. The lack of association 
may be due to several factors, including statistical chance (false negative) and/or technical issues 
in the assessment of conditioned pain modulation. The ICC for conditioned pain modulation was 
0.45, which was lower than the ICCs for the other QST measures, indicating a lower level of 
reproducibility compared to the other QST measures. In addition, the magnitude of conditioned 
pain modulation may have been affected by the choice of test and conditioning stimuli. For 
example, using cold as the test stimulus may be more sensitive than pressure, given that the cold 
pressor task was also used as the conditioning stimulus. However, a meta-analysis of conditioned 
modulation paradigms in populations with chronic pain did not find that the type of test or 
conditioning stimulus type significantly influenced the effect size (33). Additional studies, using 
different conditioned pain modulation paradigms, are needed to replicate this finding. 
Another possibility for the lack of association between conditioned pain modulation and 
disease activity measures is that conditioned pain modulation reflects a different type of pain 
pathway (34). While temporal summation is thought to reflect the facilitation of ascending 
nociceptive processing, conditioned pain modulation is considered a measure of the descending 
inhibitory pain pathways (35). We expected impaired conditioned pain modulation to be 
associated with heightened measures of disease activity due to enhanced pain sensitivity. 
However, among individuals with high inflammatory disease activity, peripheral inflammation 
may serve as an endogenous conditioning stimulus that activates the descending analgesic pain 
mechanisms. Thus, in some individuals, impairments in conditioned pain modulation may be 
associated with elevations in disease activity measures, while, in others, heightened conditioned 
pain modulation may be associated with decreases in disease activity measures. Longitudinal 
assessment of conditioned pain modulation before and after the onset of inflammation would be 
useful in disentangling these relationships. We are continuing to follow the individuals in this 
study longitudinally, as they are started on new DMARDs, which provides an opportunity to 
identify changes in conditioned pain modulation with improvements in inflammation. 
Strengths of this study include the comprehensive assessment of PPTs, temporal 
summation, and conditioned pain modulation. To our knowledge, this is the largest study of QST 
in RA, and the only study to assess PPTs, temporal summation, and conditioned pain modulation, 
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while also characterizing inflammatory disease activity and psychosocial factors. An additional 
strength is the assessment of secondary fibromyalgia in this RA cohort. However, 
misclassification may exist since the ACR 2010 modified preliminary diagnostic criteria for 
fibromyalgia are based on self-reported pain in 19 areas, fatigue, nonrestorative sleep, and 
cognitive symptoms (22). Although the 19 areas are nonjoint sites, RA patients may find it 
difficult to distinguish between pain at different locations. 
Limitations of this study include the cross-sectional design, which precludes conclusions 
involving the directionality of associations between QST measures and disease activity. 
Longitudinal data collection is ongoing, and analyses to examine associations between baseline 
QST measures and changes in inflammatory serum markers and composite RA disease activity 
measures in response to DMARD therapy are planned. The heterogeneity in the assessment of 
QST measures across sites may be another limitation. These assessments can be sensitive to 
variations in study procedures. We have made efforts to standardize protocols, including an 
intensive training session before the start of the study and visiting each site approximately 1 year 
into the study to ensure that there was no drift in technique. ICCs between the master study 
assessor and 3 other study assessors were in the fair to excellent range. When comparing QST 
measurements across sites, PPTs at the knee and trapezius were the only measures that differed 
significantly across sites (see Supplementary Table 1, available on the Arthritis Care & Research 
web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23266/abstract). This may reflect 
variations in testing procedures across sites. Alternatively, this difference may reflect differences 
in study populations across sites. To address these concerns, we included study site as a covariate 
in all analyses. 
Although we included many potential confounders of the relationship between QST 
measures and inflammatory disease activity in our models, the potential for residual confounding 
remains. While we performed a large number of statistical analyses, we avoided adjustment for 
multiple comparisons in accordance with what has been advocated in epidemiologic research 
(23). We made a conscious effort to highlight only the associations that were consistent across 
the majority of body sites or disease activity measures. 
In conclusion, pain sensitization, demonstrated by low PPTs and high temporal 
summation values at the forearm, were associated with high CDAI scores. These findings 
highlight the importance of understanding pain sensitization in RA, particularly as it relates to 
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inflammatory disease assessment. Additional studies are needed to better understand the clinical 
impact of pain sensitization on the efficacy of RA treatment.  
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Table 1. Participant characteristics (n = 139)* 
Characteristic Value 
Age, mean ± SD years 54.2 ± 13.6 
Female 83.5 
Body mass index, mean ± SD kg/m 30.9 ± 17.3 2 
Seropositive 83.5 
Disease duration, mean ± SD years 9.3 ± 12.7 
CDAI score, mean ± SD 24.4 ± 14.0 
Tender joint count in 28 joints, mean ± SD 11.4 ± 9.2 
Swollen joint count in 28 joints, mean ± SD 5.5 ± 5.1 
Patient global assessment score (0–10), mean ± SD 5.3 ± 1.8 
Assessor global assessment score (0–10), mean ± SD 3.7 ± 2.3 
Any DMARD use† 61.2 
Biologic DMARD use† 25.2 
Synthetic DMARD use† 46.0 
NSAID use 48.9 
Corticosteroid use 43.2 
Pain (0–10 NRS), mean ± SD 5.1 ± 2.3 
PROMIS depression (T score), mean ± SD 50.5 ± 9.1 
PROMIS anxiety (T score), mean ± SD 53.7 ± 8.7 
PROMIS sleep disturbance (T score), mean ± SD 54.2 ± 9.2 
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Pain Castastrophizing Scale, mean ± SD 18.4 ± 13.4 
Fibromyalgia‡ 31.7 
* Values are percentages unless otherwise indicated. CDAI = Clinical 
Disease Activity Index; DMARD = disease-modifying antirheumatic 
drug; NSAID = nonsteroidal antiinflammatory drug; NRS = numeric 
rating scale; PROMIS = Patient-Reported Outcomes Measurement 
Information System. 
† Numbers reflect DMARD use within 6 weeks of the baseline 
assessment, prior to starting their new DMARD. 
‡ Defined by the American College of Rheumatology 2010 modified 
preliminary diagnostic criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Quantitative sensory testing measures (n = 139)* 
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Measure Mean ± SD Median (IQR) 
PPT at wrist, kgf 2.9 ± 1.6 2.5 (1.9–3.8) 
PPT at knee, kgf  5.3 ± 2.7 4.9 (3.0–7.3) 
PPT at thumbnail, kgf  3.6 ± 1.9 3.1 (2.4–4.4) 
PPT at trapezius, kgf  2.9 ± 1.6 2.5 (1.9–3.5) 
Temporal summation at wrist†  15.0 ± 15.3 10.0 (2.7–23.3) 
Temporal summation at forearm† 14.0 ± 13.8 11.3 (1.7–22.0) 
Conditioned pain modulation‡ 142.3 ± 39.4 132.6 (117.7–155.7) 
* PPT = pressure pain threshold. 
† Calculated as the difference between the maximum pain rating at the tenth 
tap minus the pain rating at the first tap. 
‡ Calculated as PPT2/PPT1 × 100. 
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Table 3. Relationship of pressure pain thresholds to RA disease activity* 
 TJC SJC PtGA EGA CDAI 
Overall study cohort      
   Wrist, adj. β −1.65 −0.46 −0.25 −0.30 −2.66  
      P < 0.0001† 0.09 0.04† 0.01† < 0.0001† 
   Knee, adj. β −1.12 −0.17 −0.16 −0.13 −1.58 
      P < 0.0001† 0.32 0.03† 0.09 0.0001† 
   Thumbnail, adj. β −1.09 0.02 −0.10 −0.11 −1.29 
      P 0.002† 0.95 0.32 0.31 0.03† 
   Trapezius, adj. β −1.98 −0.47 −0.40 −0.44 −3.30 
      P < 0.0001† 0.12 0.002† 0.0009† < 0.0001† 
RA patients without FM (n = 95)      
   Wrist, adj. β −1.94 −0.53 −0.33 −0.31 −3.11  
      P < 0.0001† 0.09 0.03† 0.03† < 0.0001† 
   Knee, adj. β −0.81 −0.06 −0.16 −0.06 −1.09 
      P 0.001† 0.73 0.06 0.46 0.009† 
   Thumbnail, adj. β −0.99 0.08 −0.13 −0.03 −1.08 
      P 0.004† 0.76 0.28 0.79 0.07 
   Trapezius, adj. β −1.68 −0.30 −0.41 −0.38 −2.78 
      P < 0.0001† 0.32 0.005† 0.005† < 0.0001† 
RA patients with FM (n = 44)      
   Wrist, adj. β −1.07 −0.21 −0.08 −0.28 −1.64  
      P 0.25 0.70 0.73 0.23 0.22 
   Knee, adj. β −1.66 −0.06 −0.08 −0.23 −2.02 
      P 0.009† 0.88 0.62 0.16 0.03† 
   Thumbnail, adj. β −1.63 −0.40 −0.04 −0.41 −2.48 
      P 0.08 0.48 0.86 0.07 0.06 
   Trapezius, adj. β −3.79 −0.96 −0.29 −0.68 −5.72 
      P 0.009† 0.29 0.40 0.07 0.006† 
* Adjusted for age, sex, seropositivity, RA disease duration, body mass index, depression, sleep 
disturbance, and pain catastrophizing. RA = rheumatoid arthritis; TJC = tender joint count; SJC = 
swollen joint count; PtGA = patient global assessment; EGA = evaluator global assessment; CDAI = 
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Clinical Disease Activity Index; adj. = adjusted; FM = fibromyalgia. 
† Statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Relationship of temporal summation and conditioned pain modulation to RA disease 
activity in the overall study cohort (n = 139)* 
 TJC SJC PtGA EGA CDAI 
Temporal summation (forearm), adj. β 0.11 −0.009 0.05 0.04 0.19 
   P 0.02† 0.80 0.0006† 0.01† 0.02† 
Temporal summation (wrist) , adj. β 0.07 −0.02 0.04 0.02 0.11 
   P 0.10 0.56 0.003† 0.10 0.12 
Conditioned pain modulation, adj. β 0.04 −0.001 −0.001 −0.004 0.03 
   P 0.03† 0.91 0.77 0.47 0.27 
* Adjusted for age, sex, seropositivity, RA disease duration, body mass index, depression, sleep 
disturbance, and pain catastrophizing. RA = rheumatoid arthritis; TJC = tender joint count; SJC = 
swollen joint count; PtGA = patient global assessment; EGA = evaluator global assessment; CDAI = 
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Clinical Disease Activity Index; adj. = adjusted. 
† Statistically significant. 
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